文献速递骨质疏松与钙磷/甲状旁腺甲状腺疾病垂体与肾上腺疾病

Sanjad-Sakati综合征疾病谱与死亡率的国际罕见病注册研究

Comprehensive analysis of disease spectrum and mortality in Sanjad-Sakati syndrome: an international rare disease registry study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该国际多中心注册研究纳入135例Sanjad-Sakati综合征患者,中位年龄9.1岁,所有基因检测者均携带TBCE founder突变。内分泌表现包括全例甲状旁腺功能减退、16.5%原发性甲状腺功能减退、27.8%低血糖等;中位生存期27.2年,84%死亡由呼吸衰竭导致,18岁总体生存率62.4%。

要点

  • SSS患者均存在甲状旁腺功能减退,需警惕低钙血症相关表现。
  • 呼吸衰竭是主要死因,占死亡病例84%,应加强呼吸系统监测。
  • 中位生存期27.2年,18岁生存率62.4%,需多学科长期管理。

核心结论

  • SSS患者内分泌、呼吸及胃肠道表现发生率高,呼吸衰竭为首位死因,需制定多学科诊疗指南。

研究设计与样本

  • 国际多中心罕见病注册研究,通过REDCap调查收集海湾地区多个中心135例SSS患者的临床与遗传数据。

主要发现

  • 所有基因检测者(n=68)均检出纯合TBCE founder突变(c.155_166del; p.Ser52_Gly55del)。
  • 内分泌表现:全例甲状旁腺功能减退,原发性甲状腺功能减退16.5%,低血糖27.8%,非自身免疫性胰岛素依赖型糖尿病1.6%,垂体激素缺乏。
  • 其他表现:发育迟缓100%,低钙惊厥64.2%,手足抽搐53.3%,肾钙质沉着62.1%,胃食管反流29.1%,反复呼吸道感染63.7%,细菌感染53.8%。
  • Kaplan-Meier分析估计中位生存期27.2年,呼吸衰竭导致84%(21/25)的死亡,18岁总体生存率62.4%。

关键数值与推荐

  • 宫内生长受限普遍存在,平均出生体重-3.0 SD,出生身长-3.3 SD。
  • 出生后生长显示婴儿期严重生长迟缓,身高z评分持续低至-7至-8。
  • 35%患者使用抗生素预防。

临床怎么用

  • 对SSS患者应常规评估甲状旁腺功能、甲状腺功能、血糖及垂体激素。
  • 需监测低钙血症相关惊厥、手足抽搐及肾钙质沉着,并关注呼吸系统并发症。
  • 建议多学科团队管理,包括内分泌科、呼吸科和消化科。

局限性

  • 数据来源于海湾地区多个中心,可能存在注册偏倚。
  • 遗传检测仅在68例患者中完成,其余患者基因型未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Sanjad-Sakati syndrome (SSS), also known as hypoparathyroidism-intellectual disability-dysmorphism syndrome, is a rare autosomal recessive disorder caused by a TBCE founder mutation. The full disease spectrum remains poorly understood. OBJECTIVES: To comprehensively analyze growth, phenotype, endocrine manifestations, and mortality in a large multicenter SSS cohort. METHODS: Clinical and genetic data were collected from 135 individuals across centers in the Gulf region using a REDCap survey. RESULTS: The median age at inclusion was 9.1 years (range: birth-30 years; 50.3% female). The homozygous TBCE founder mutation (c.155_166del; p.Ser52_Gly55del) was detected in all genetically tested individuals (n = 68). Intrauterine growth restriction (mean birth weight -3.0 SD, length -3.3 SD) and dysmorphic features were universal. Postnatal growth showed severe failure to thrive during infancy, followed by persistently low height z-scores (-7 to -8). Endocrine features included hypoparathyroidism in all patients, primary hypothyroidism (16.5%), hypoglycemia (27.8%), nonautoimmune insulin-dependent diabetes (1.6%) and pituitary hormone deficiencies. Other findings included developmental delay (100%), hypocalcemic seizures (64.2%), tetany (53.3%), nephrocalcinosis (62.1%), gastroesophageal reflux (29.1%), and recurrent respiratory (63.7%) and bacterial infections (53.8%). Antibiotic prophylaxis was used in 35% of patients. Kaplan-Meier analysis estimated a median survival of 27.2 years, with respiratory failure causing 84% of deaths (21/25). The estimated overall survival at an age of 18 years was 62.4%. CONCLUSION: This largest reported SSS cohort highlights the high prevalence of associated endocrine, respiratory, and gastrointestinal manifestations, with respiratory failure as the leading cause of death. These data support the need for multidisciplinary care guidelines.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Almutair A, Karas K, Al Subaihin A, et al. Comprehensive analysis of disease spectrum and mortality in Sanjad-Sakati syndrome: an international rare disease registry study. J Clin Endocrinol Metab. 2026. PMID: 42267904. doi:10.1210/clinem/dgag226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。